Polyphyllin VII protects from breast cancer-induced osteolysis by suppressing osteoclastogenesis via c-Fos/NFATc1 signaling
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110316 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Qin Yang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Anti-inflammatory and Immunomodulatory Pharmacology, Innovation Program of Drug Research on Inflammatory and Immune Diseases, NMPA Key …. Hauptthemen laut MEDLINE: Osteolysis, Saponins, Bone Resorption, Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Bone is a preferred metastatic site of advanced breast cancer and the 5-year overall survival rate of breast cancer patients with bone metastasis is only 22.8%. Targeted inhibition of osteoclasts can treat skeletal-related events (SREs) in breast cancer patients. Polyphyllin VII (PP7), a pennogenyl saponin isolated from traditional Chinese herb Paris polyphylla, exhibits strong anti-inflammatory and anti-cancer activities. In this study, we evaluated the effect of PP7 on metastatic breast cancer-induced bone destruction in vivo and the underlying mechanisms. We found that intraperitoneal injection of 1 mg/kg PP7 significantly ameliorated the breast cancer MDA-MB-231 cell-induced osteolysis in mice. Mechanistically, PP7 (0.125-0.5 μM) inhibited the conditioned medium of MDA-MB-231 cells (MDA-MB-231 CM)-induced osteoclast formation in bone marrow-derived macrophages (BMMs). Furthermore, PP7 markedly reduced MDA-MB-231 CM-induced osteoclastic bone resorption and F-actin rings formation in vitro. During MDA-MB-231 CM-induced osteoclastogenesis, the activation of c-Fos and NFATc1 signaling was significantly downregulated by PP7, and finally osteoclast-related genes such as Oscar, Atp6v0d2, Mmp9 and β3 integrin were decreased. In addition, the formation of osteoblast was promoted by PP7 treatment. Our current findings revealed PP7 as a potential safe agent for preventing and treating bone destruction in breast cancer patients with bone metastases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Anti-inflammatory and Immunomodulatory Pharmacology, Innovation Program of Drug Research on Inflammatory and Immune Diseases, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong…
- Breast Center, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yang, Q., Guo, J., Zheng, J., Chen, Y., Zou, B., Li, R., Ding, Z., Wang, Y., Li, L., Chen, Z., Mo, L., Liang, Q., Chen, F., & Li, X. (2023). Polyphyllin VII protects from breast cancer-induced osteolysis by suppressing osteoclastogenesis via c-Fos/NFATc1 signaling. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110316
Vancouver
Yang Q, Guo J, Zheng J, Chen Y, Zou B, Li R, et al. Polyphyllin VII protects from breast cancer-induced osteolysis by suppressing osteoclastogenesis via c-Fos/NFATc1 signaling. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110316
BibTeX
@article{Yang2023,
author = {Yang, Qin and Guo, Jingyun and Zheng, Jiehuang and Chen, Yan and Zou, Binhua and Li, Ruopeng and Ding, Zongbao and Wang, Yiyuan and Li, Lihong and Chen, Ziye and Mo, Lixia and Liang, Qinghe and Chen, Fengsheng and Li, Xiaojuan},
title = {Polyphyllin VII protects from breast cancer-induced osteolysis by suppressing osteoclastogenesis via c-Fos/NFATc1 signaling},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110316}
}
EUVIMED